Granted Patent
B2
US 12,215,093 · App. 18/467,022 · Granted Feb 4, 2025
Bicyclic carboxamides and methods of use thereof
Inventors:
Yalda Bravo (San Diego, CA); Austin Chih-Yu Chen (San Marcos, CA); Jinyue Ding (Burnaby, CA); Robert Gomez (North Vancouver, CA); Heather Lam (Scarborough, CA); Joe Fred Nagamizo (San Diego, CA); Renata Marcella Oballa (Coquitlam, CA); David Andrew Powell (Vancouver, CA); Tao Sheng (Coquitlam, CA)
Assignee:
TEMPEST THERAPEUTICS, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compounds, compositions and methods are provided for modulating the activity of EP 2 and EP 4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP 2 and EP 4 receptors. In certain embodiments, the compounds are antagonists of both the EP 2 and EP 4 receptors.
Claims (31)
1. A method for the treatment of an EP4-mediated cancer in a patient comprising administering to the patient a compound that is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
5. The method of claim 4 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
8. The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
10. The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
11. The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
12. The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
13. The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
14. The method of claim 1 , wherein the EP4-mediated cancer is selected from glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer and prostate cancer.
15. The method of claim 1 , wherein the EP4-mediated cancer is selected from colon cancer, bladder cancer, hepatocellular carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer.
16. The method of claim 1 , wherein the EP4-mediated cancer selected from colorectal cancer (CRC), lung cancer, squamous cell carcinoma of the head and neck (SCCHN), bladder cancer, endonetrial cancer, and gastric cancer.
17. The method of claim 1 , wherein the EP4-mediated cancer is colorectal cancer (CRC).
18. The method of claim 1 , wherein the EP4-mediated cancer is endometrial cancer.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 22, 2023
From: BRAVO, YALDA; CHEN, AUSTIN CHIH-YU; NAGAMIZO, JOE FRED
To: INCEPTION SCIENCES, INC.
Reel/Frame 064998/0378 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 22, 2023
From: DING, JINYUE; GOMEZ, ROBERT; LAM, HEATHER; OBALLA, RENATA MARCELLA; POWELL, DAVID ANDREW; SHENG, TAO
To: INCEPTION SCIENCES CANADA, INC.
Reel/Frame 064998/0574 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 22, 2023
From: INCEPTION SCIENCES, INC.; INCEPTION SCIENCES CANADA, INC.
To: TEMPEST THERAPEUTICS, INC.
Reel/Frame 064998/0757 →
Continuity (6)
Provisional Application
62746843
· Oct 17, 2018
Provisional Application
62659068
· Apr 17, 2018
References Cited (131)
US 7029674B2
· Carreno et al.
· 2006
[cited by applicant]
US 7488802B2
· Collins et al.
· 2009
[cited by applicant]
US 7521051B2
· Collins et al.
· 2009
[cited by applicant]
US 7803841B2
· Oxford et al.
· 2010
[cited by applicant]
US 8008449B2
· Korman et al.
· 2011
[cited by applicant]
US 8158671B2
· Boyd et al.
· 2012
[cited by applicant]
US 8217149B2
· Irving et al.
· 2012
[cited by applicant]
US 8354509B2
· Carven et al.
· 2013
[cited by applicant]
US 8383796B2
· Korman et al.
· 2013
[cited by applicant]
US 8552154B2
· Freeman et al.
· 2013
[cited by applicant]
US 8617546B2
· Kang et al.
· 2013
[cited by applicant]
US 8685394B2
· Jure-Kunkel
· 2014
[cited by applicant]
US 8709417B2
· Allison et al.
· 2014
[cited by applicant]
US 20110028463A1
· Nozawa et al.
· 2011
[cited by applicant]
EP 2172447A1
· 2010
[cited by applicant]
EP 2277858A1
· 2011
[cited by applicant]
JP 2007023028A
· 2007
[cited by applicant]
JP 2017528477A
· 2017
[cited by applicant]
WO WO2007143825A1
· 2007
[cited by applicant]
WO WO2008104055A1
· 2008
[cited by applicant]
WO WO2009005076A1
· 2009
[cited by applicant]
WO WO2009139373A1
· 2009
[cited by applicant]
WO WO2010121382A1
· 2010
[cited by applicant]
WO WO2010121385A1
· 2010
[cited by applicant]
WO WO2012024376A1
· 2012
[cited by applicant]
WO WO2017103851A1
· 2017
[cited by applicant]
WO WO2018008711A1
· 2018
[cited by applicant]
WO WO2018195123A1
· 2018
[cited by applicant]
WO WO2019204523A1
· 2019
[cited by applicant]
US 11,440,897 B2, 09/2022, Bravo et al. (withdrawn)
[cited by applicant]
No new references cited by the Examiner.
[cited by examiner]
Abraham et al. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Alimet. Pharmacal. Ther. 25:913-924 (2007).
[cited by applicant]
Adams et al. Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov. 14:603-622 (2015).
[cited by applicant]
Albu et al. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity. Oncoimmunology 6:e1338239 (2017).
[cited by applicant]
Arosh et al. Molecular and preclinical basis to inhibit PGE2 receptors EP2 and EP4 as a novel nonsteroidal therapy for endometriosis. PNAS USA 112:9716-9721 (2015).
[cited by applicant]
Arthritis: Causes, Signs, and Diagnosis [online] retrieved from the internet on Aug. 29, 2021; URL: https://www.healthline.com/health/arthritis.
[cited by applicant]
Bae. Cancer Targeted Drug Delivery. Springer: New York (p. v) (2013).
[cited by applicant]
Banker et al. Modern Pharmaceutices. 3rd ed. Marcel Dekker, New York (pp. 451 & 596) (1996).
[cited by applicant]
Beaumont et al. Design of Ester Prodrugs to Enhance Oral Absorption of Poorly Permeable Compounds: Challenges to the Discovery Scientist. Current Drug Metabolism 4:461-485 (2003).
[cited by applicant]
Benz. The Jeremiah Metzger Lecture Cancer in the Twenty-First Century: An Inside View From an Outsider Transactions of the American Clinical and Climatological Association 128:275-297 (2017).
[cited by applicant]
Berge et al. Pharmaceutical Salts. Journal of Pharmaceutical Sciences 66(1):1-19 (Jan. 1977).
[cited by applicant]
Braun et al. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106(7):2375-2381 (2005).
[cited by applicant]
Cancer [online], retrieved from the Internet on Jul. 6, 2007, URL: http://www.nlm.nih.gov/medlineplus/cancer.html.
[cited by applicant]
Cao et al. Prostaglandin receptor EP4 in abdominal aortic aneurysms. Am J Pathol 181:313-321 (2012).
[cited by applicant]
Chandrasekhar et al. Analgesic and anti-inflammatory properties of novel, selective, and potent EP4 receptor antagonists. Pharmacal Res Perspect. 5(3):e00316 (2017).
[cited by applicant]
Chang et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. PNAS USA 101:591-596 (2004).
[cited by applicant]
Chen et al. A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. British J. Pharmacol. 160:292 (2010).
[cited by applicant]
Chen et al. Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression. Breast Cancer Research 16:410-424 (2014).
[cited by applicant]
Cipollone et al. Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. Aterioscler Thromb Vasc Biol 25:1925-1931 (2005).
[cited by applicant]
Clark et al. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammati…
[cited by applicant]
Colucci et al. Discovery of 4-{1[({144-(trifluoronnethyl)benzy11-1H-indo1-7-yllcarbonyl) amino]cyclopropyl}benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain. Bioorganic &…
[cited by applicant]
Damasio. Alzheimer's Disease and Related Dementias. Cecil Textbook of Medicine, 20th edition, 2:1992-1996 (1996).
[cited by applicant]
Damia et al. Contemporary pre-clinical development of anticancer agents—What are the optimal preclinical models? European Journal of Cancer 45:2768-2781 (2009).
[cited by applicant]
Doherty et al. Proneoplastic effects of PGE mediated by EP4 receptor in colorectal cancer. BMC Cancer 9:207 (2009).
[cited by applicant]
Dolgin. Oncogene-specific advocacy groups bring a patient-centric perspective to studies of lung cancer. Nature 587:S16-S17 (2020).
[cited by applicant]
Dounay et al. Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway. J. Med. Chem 58:8762-8782 (2015).
[cited by applicant]
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003]. Retrieved from the internet, URL;http;//www.cnn/com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html.
[cited by applicant]
Ferreira et al. Chapter 6: The Importance of Cancer Cell Lines as in vitro Models in Cancer Methylome Analysis and Anticancer Drugs Testing. Oncogenomics and Cancer Proteomics—Novel Approaches in Biomarkers Discovery an…
[cited by applicant]
Flesch et al. Novel prostaglandin receptor modulators—Part II: EP receptor modulators; a patent review (2002-2012). Expert Opin Ther Pat 23(2):233-267 (2013).
[cited by applicant]
Freireich et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50:219-244 (1966).
[cited by applicant]
Fulton et al. Targeting Prostaglandin E EP Receptors to Inhibit Metastasis. Cancer Research 66(20):9794-9797 (2006).
[cited by applicant]
Gabitass et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-1…
[cited by applicant]
Golub et al.; Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 286(5439):531-537 (1999).
[cited by applicant]
Hata et al. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacal. Ther. 103:147-166 (2004).
[cited by applicant]
Hayat. Autophagy Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging. Academic Press: Sand Diego 5:xxi (2015).
[cited by applicant]
Hizaki et al. Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). PNAS USA 96:10501-10506 (1999).
[cited by applicant]
Holt et al. Prostaglandin E (PGE) suppresses natural killer cell function primarily through the PGE receptor EP4. Cancer Immunology Immunotherapy 60(11):1577-1586 (2011).
[cited by applicant]
Hoshino et al. Improvement of cognitive function in Alzheimer's disease model mice by genetic and pharmacological inhibition of the EP(4) receptor. J Neurochem. 120:795-805 (2012).
[cited by applicant]
IUPAC-IUB Comm. Biochem. Nomenclature. IUPAC-IUB [International Union of Pure and Applied Chemistry-International Union of Biochemistry] Commission of Biochemical Nomenclature. Abbreviated nomenclature of synthetic poly…
[cited by applicant]
Jiang et al. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. PNAS USA 110:3591-3596 (2013).
[cited by applicant]
Jiang et al. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Trends in Pharm Sci. 34:413-423 (2013).
[cited by applicant]
Jiang et al. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. PNAS USA 109:3149-3154 (2012).
[cited by applicant]
Jochems et al. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. Oncotarget 7:37762-37772 (2016).
[cited by applicant]
Johnson et al., Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British Journal of Cancer 84(10):1424-1431 (2001).
[cited by applicant]
Kalinski. Regulation of immune responses by prostaglandin E2. J Immunol. 188:21-28 (2012).
[cited by applicant]
Kundu et al. Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties. Breast Cancer Research and Treatment 143(1):19-31 (2014).
[cited by applicant]
Lala et al. Role of nitric oxide in tumor progression: Lessons from experimental tumors. Cancer and Metastasis Reviews 17(1):91-106 (1998).
[cited by applicant]
Layzer. Section Five—Degenerative Diseases of the Nervous System. Cecil Textbook of Medicine, 20th edition, 2:2050-2057 (1996).
[cited by applicant]
Ledford. US cancer institute overhauls cell lines. Nature 530:391 (Feb. 25, 2016).
[cited by applicant]
Legler et al. Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int. J. Biochem. Cell Biol. 42:198-201 (2010).
[cited by applicant]
Liu et al. Highly efficient route to fused polycyclic aromatics via palladium-catalyzed aryne annulation by aryl halides. J. Org. Chem. 72(1):223-232 (2007).
[cited by applicant]
Ma et al. Definition of Prostaglandin E2-EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth. Cancer Res. 75:2822-2832 (2015).
[cited by applicant]
Ma et al. Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities. Mol. Cancer Res. 8:1310-1318 (2010).
[cited by applicant]
Mahic et al. FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J. Immunol. 177:246-254 (2011).
[cited by applicant]
Maley et al. Frontiers in Cancer Research Springer pp. 18-19 (2016).
[cited by applicant]
Mao et al. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin. Cancer Res. 20:4096-4106 (2014).
[cited by applicant]
Marcias-Perez et al. Mouse EP3 α, β, and γ Receptor Variants Reduce Tumor Cell Proliferation and Tumorigenesis in Vivo. J. Bio. Chem. 283:12538-12545 (2008).
[cited by applicant]
Markovič et al. Structural features of subtype-selective EP receptor modulators. Drug Discovery Today 22(1):57-71 (2016).
[cited by applicant]
Matsumoto et al. Diversification of cyclooxygenase-2-derived prostaglandins in ovulation and implantation. Biol Reprod 64:1557-1565 (2001).
[cited by applicant]
Naing et al. Preclinical investigations and a first-inhuman phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors. Jou…
[cited by applicant]
Nakanishi et al. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis. 32:1333-1339 (2011).
[cited by applicant]
Ocana et al. Preclinical development of molecular targeted agents for cancer. Nat Rev Clin Oncol 8:200-209 (2011).
[cited by applicant]
Ochs et al. Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4. J. Neurochem. 136:1142-1154 (2016).
[cited by applicant]
PCT/US2018/028034 International Search Report and Written Opinion dated Jul. 6, 2018.
[cited by applicant]
PCT/US2019/027992 International Search Report and Written Opinion dated Jul. 5, 2019.
[cited by applicant]
Platten et al., Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol. 5:673 (2015).
[cited by applicant]
Prasanna et al. Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models. Experimental Eye Research 89:608-617 (2009).
[cited by applicant]
Qian et al. Macrophage diversity enhances tumor progression and metastasis. Cell. 141:39-51 (2010).
[cited by applicant]
Rautio et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov 7(3):255-270 (2008).
[cited by applicant]
Ravin. Chapter 76: Preformulation. Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa. (pp. 1409-1423) (1985).
[cited by applicant]
Sharma et al. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature Reviews Cancer 10:241-253 (Apr. 2010).
[cited by applicant]
Shoji et al. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 53:1151-1158 (2004).
[cited by applicant]
Sonoshita et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat. Med. 7:1048-1051 (2001).
[cited by applicant]
Stepan et al., Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active y-secretase inhibitor, J. Med. Chem., 55(7):3414-24 (2012).
[cited by applicant]
Sung et al. Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res. 65:9304-9311 (2005).
[cited by applicant]
Sung et al. Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development. Oncogene 25:5507-5516 (2006).
[cited by applicant]
Take et al. Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action. Front Immunol 11:324 (2020).
[cited by applicant]
Terada et al. Identification of EP4 as a Potential Target for the Treatment of Castration—Resistant Prostate Cancer Using a Novel Xenograft Model. Cancer Research 70(4):1606-1615 (2010).
[cited by applicant]
U.S. Appl. No. 16/387,294 Office Action dated Mar. 25, 2020.
[cited by applicant]
U.S. Appl. No. 16/387,294 Office Action dated Oct. 4, 2019.
[cited by applicant]
U.S. Appl. No. 16/605,408 Office Action dated Aug. 11, 2022.
[cited by applicant]
U.S. Appl. No. 16/880,756 Office Action dated Jan. 13, 2021.
[cited by applicant]
U.S. Appl. No. 16/880,756 Office Action dated Oct. 20, 2020.
[cited by applicant]
U.S. Appl. No. 17/070,554 Office Action dated Sep. 2, 2021.
[cited by applicant]
U.S. Appl. No. 17/354,010 Office Action dated Aug. 30, 2022.
[cited by applicant]
U.S. Appl. No. 17/847,811 Office Action dated Feb. 27, 2023.
[cited by applicant]
Wang et al. Prostaglandin E Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. Gastroenterology 149(7):1884-1895 (2015).
[cited by applicant]
Wang et al. The Role of Prostaglandin E(2) in Tumor-Associated Immunosuppression. Trends Mol Med 22:1-3 (2016).
[cited by applicant]
Whiteside et al. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 10:1019-1035 (2010).
[cited by applicant]
Wiemer et al. A live imaging cell motility screen identifies prostaglandin E2 as a T cell stop signal antagonist. J. Immunology 187:3663 (2011).
[cited by applicant]
Wolff. Burger's Medicinal Chemistry and Drug Discovery. 5th Ed. Part 1, pp. 975-977 (1995).
[cited by applicant]
Yamane et al. Prostaglandin E(2) receptors, EP2 and EP4, differentially modulate TNF-alpha and IL-6 production induced by lipopolysaccharide in mouse peritoneal neutrophils. Biochem. Biophys. Res. Commun. 278:224-228 (2…
[cited by applicant]
Yang et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest. 111:727-735 (2003).
[cited by applicant]
Zelenay et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell 162:1257-1270 (2015).
[cited by applicant]
Cancer [online], retrieved from the Internet on May 3, 2024, URL: http://www.https://en.wikipedia.org/wiki/Cancer.
[cited by applicant]